[To learn English]
The U.S. FDA on Monday approved an at-home starting dose of Eisai’s and Biogen’s Alzheimer’s drug, allowing some patients to begin therapy with injections administered by themselves or a caregiver. Shares of Biogen were up 4.5% in afternoon trading.
The approval applies to an under-the-skin formulation of the drug branded as Leqembi. Until now, patients starting treatment received the drug through intravenous infusions, typically given at a clinic, and could later switch to maintenance treatment after 18 months.
美国FDA周一批准了卫材和百健阿尔茨海默病药物的居家起始剂量，允许部分患者自行或由护理人员注射开始治疗。百健股价午后上涨4.5%。
该批准适用于名为Leqembi的皮下注射剂型。在此之前，患者起始治疗需通过静脉输注给药（通常在诊所进行），并在18个月后转为维持治疗。
LearnEnglish Leave a remark